NASDAQ:XENE - Xenon Pharmaceuticals Stock Price, Forecast & News

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Xenon Pharmaceuticals Inc (NASDAQ:XENE) issued its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.49) by $0.16. The biopharmaceutical company earned $3.50 million during the quarter. View Xenon Pharmaceuticals' Earnings History.

Xenon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Xenon Pharmaceuticals.

3 analysts have issued 1-year price objectives for Xenon Pharmaceuticals' shares. Their forecasts range from $18.00 to $25.00. On average, they anticipate Xenon Pharmaceuticals' share price to reach $21.50 in the next year. This suggests a possible upside of 40.6% from the stock's current price. View Analyst Price Targets for Xenon Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xenon Pharmaceuticals.

Media stories about XENE stock have been trending somewhat negative on Tuesday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Xenon Pharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Xenon Pharmaceuticals.

Xenon Pharmaceuticals saw a decline in short interest in January. As of January 15th, there was short interest totalling 429,800 shares, a decline of 24.4% from the December 31st total of 568,400 shares. Based on an average daily volume of 177,000 shares, the short-interest ratio is currently 2.4 days. Approximately 2.1% of the shares of the company are short sold. View Xenon Pharmaceuticals' Current Options Chain.

Some companies that are related to Xenon Pharmaceuticals include Alder Biopharmaceuticals (ALDR), Ligand Pharmaceuticals (LGND), Constellation Pharmaceuticals (CNST), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Innoviva (INVA), Amneal Pharmaceuticals (AMRX), BELLUS Health (BLUSF), Y-mAbs Therapeutics (YMAB), TG Therapeutics (TGTX), Endo International (ENDP), Esperion Therapeutics (ESPR), Dicerna Pharmaceuticals (DRNA), Intra-Cellular Therapies (ITCI) and Nabriva Therapeutics (NBRV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Fate Therapeutics (FATE), Nektar Therapeutics (NKTR), Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Exelixis (EXEL), Galmed Pharmaceuticals (GLMD), Karyopharm Therapeutics (KPTI) and Sucampo Pharmaceuticals (SCMP).

Xenon Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (3.83%) and California Public Employees Retirement System (0.23%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab and Simon N Pimstone. View Institutional Ownership Trends for Xenon Pharmaceuticals.

XENE stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, Mohammad Azab and Simon N Pimstone. View Insider Buying and Selling for Xenon Pharmaceuticals.

XENE stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC. View Insider Buying and Selling for Xenon Pharmaceuticals.

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XENE stock can currently be purchased for approximately $15.29.

Xenon Pharmaceuticals has a market capitalization of $395.54 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-34,500,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe.View Additional Information About Xenon Pharmaceuticals.

The official website for Xenon Pharmaceuticals is http://www.xenon-pharma.com/.

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]